<DOC>
	<DOCNO>NCT01491932</DOCNO>
	<brief_summary>This study evaluate long-term safety , tolerability efficacy AFQ056 patient complete AFQ056A study Parkinson 's disease L-dopa induce dyskinesia ( PD-LID ) .</brief_summary>
	<brief_title>Open-label , Long-term Safety Extension Study AFQ056 Parkinson 's Patients With L-dopa Induced Dyskinesias</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients complete previous AFQ056A study eligible define core study protocol Outpatients Patients primary caregiver willing able ass condition patient throughout study accordance protocol requirement Atypical secondary form Parkinson 's disease History surgical treatment PD include deep brain stimulation Advanced , severe , unstable disease ( PD ) History malignancy Evidence dementia Untreated/ineffectively treat mental disorder Treatment certain prohibit medication Abnormal lab value heart abnormalities Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>